Patent Applications Filed for Burn, Scar and Wound Healing Aids and Bandages
IRVINE, CA–(Marketwired – May 4, 2015) – NuGene International, Inc. (“NuGene”) (OTCQB:NUGN), the maker of age-defying aesthetic products for skin and hair rejuvenation, has filed new patents to protect proprietary claims directed to bandages treated with Human Adipose Derived Stem Cell Cultured (HADSCC) media in a variety of formats including nanoencapsulated media dried to the dressings.
“These developments reinforce our stated goals of developing new standards of care in burn, scar and wound healing,” stated NuGene CEO Ali Kharazmi when announcing the patent filing. “Our research and development scientists are continually developing new and innovative uses of our patent pending technologies as they relate to human adipose derived stem cell media and nanoencapsulation.”
Adult adipose human stem cells are undifferentiated cells found throughout the body in fatty tissues that multiply by cell division to replenish dying cells and regenerate tissues. NuGene has developed a proprietary process to extract human adult stem cells from fat cells that the Company can use as the foundation of the formulation for its products. Using cutting edge cell science and cell biology, NuGene has been successful in mass producing biologically active growth factors derived from adipose stem cells.
One of the material challenges of skincare science is the delivery of active ingredients to the skin. NuGene met this challenge by using a proprietary nanocapsulation technology. It allows the Company to effectively deliver adipose stem cell-derived cytokines and growth factors by embedding them within a nanocapsule. This added step enhances the penetration of these biomolecules into the skin cells.
NuGene has filed a patent application to protect its proprietary processes and to create a foundation for additional patents and claims as the company continues its research in developing advanced skin care treatments and processes. The Company has previously announced the creation of a wholly owned subsidiary, NuGene BioPharma Inc., for the development of stem cell derived treatments that may require FDA approval.
About NuGene International, Inc.
NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the “next evolution of medical treatments.” The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene’s cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene’s exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has two patents pending covering 15 unique applications and inventions. NuGene’s goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.
NuGene has filed a US provisional patent application including claims directed to wound and surgical dressings including various forms of the Company’s proprietary stem cell culture medium. While there is no guaranty that a patent will issue with such claims, the Company believes that the products described in the patent application offer advantages over others presently available. This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene’s filings with the Securities and Exchange Commission, especially those risks and other matters described under “Risk Factors” within NuGene’s Form 8-K filed with the Commission on January 6, 2015 and in its Annual Report on Form 10-K filed with the Commission on March 30, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.